



Scientific Committee on Consumer Safety (SCCS)

WG on Methodologies

Venue: Luxembourg

Meeting date: 28 March 2014

Minutes

1. WELCOME AND APOLOGIES

The Chair welcomed the participants. There was no apology. Cosmetics Europe (CoE) was invited to participate to the dedicated morning session.

2. ADOPTION OF THE AGENDA

The agenda was adopted as presented.

3. DECLARATION OF INTEREST ON MATTERS ON THE AGENDA

No declaration of potential conflict of interest was made.

4. LOW BIOAVAILABILITY PRESENTATIONS

- Introduction by the Chair: How to deal with low dermal absorption (DA) of cosmetic ingredients?
- Ursula Gundert-Remy: Toxicokinetic aspects of low dermal bioavailability
- Judith Madden: In silico tools for predicting ADME properties relevant to cosmetics: Interim report of activities in the COSMOS project
- Dagmar Bury, CoE: Low dermal bioavailability in practice: Compilation/examples of substances and analytical arguments for a cut-off value
- Vera Rogiers: The SCCS Database: retrospective analysis of the dermal absorption values obtained for ANNEX substances with focus on low bioavailability
- General discussion, conclusions, next steps and further follow-up took place

5. INTERNAL MEETING OF THE WG METHODOLOGIES

- Feedback from the morning meeting on low bioavailability
- BMD approach: introduction from the Chair and examples from SCCS members
- Bernard Bottex, EFSA: Use of the Benchmark Dose approach in Risk Assessment by EFSA Panels
- Discussion on the BMD approach

6. ANY OTHER BUSINESS

Next meeting is planned for 21 May 2014

Attendance list of participants from Cosmetics Europe:

- Dr Patric Amcoff, Interim Director Science & Research, Cosmetic Europe
- Dr Judith GIERNOTH, Cosmetic Europe
- Dr Dagmar BURY, Cosmetic Europe